Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
about
Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose OptimizationBarriers to oral medication adherence for adolescents with inflammatory bowel disease.Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.Pharmacogenomics and IBD: TPMT and thiopurines.Review article: monitoring of immunomodulators in inflammatory bowel disease.IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.Review article: thiopurines in inflammatory bowel disease.Medication adherence and quality of life in pediatric inflammatory bowel diseaseObjective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease.Medical treatment of ulcerative colitisOptimizing thiopurine therapy in inflammatory bowel disease.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.A Physician's Guide to Azathioprine Metabolite Testing.Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it?Start low, go slow, but don't go this way yet.Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel diseases during long-term thiopurine administration.Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease.Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine.Is less more: does leukopenia predict remission in patients with inflammatory bowel disease receiving thiopurine treatment?A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease.Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn’s Disease.
P2860
Q28546915-506C7003-5483-4734-A1F6-1AE3BDC2FB17Q33988555-E81BE10F-13D5-4507-B7D9-5EB85BA7805FQ35595299-1D11AD95-4580-43FC-BE2B-D516546C11EFQ35596702-CD40E4C1-3617-4359-A98C-53F525F8CB05Q35787643-69B9D36C-A81E-45E7-9572-EFC91465D1FDQ36041146-5BADE400-29E3-4768-A93C-1AFA22AF18E4Q36535994-4F23C6D6-658B-4A57-9F46-968B6D017C10Q36570796-7C904518-9901-4D71-99AD-7F42818AC1C2Q36805208-97548921-755A-4822-A131-FC4B8F0C5434Q37145517-DC425E26-4BF7-41DB-A32C-CFB10A226D78Q37427481-EFF22260-540C-4C83-9D6A-11BC7B5116B5Q37800458-A23582EC-1407-4AEE-AE06-B0A83291EEBBQ38417177-B5978156-CA92-44BB-9684-C0919A235270Q40361187-08D736E1-83CB-4006-A4F0-1F8F82A12493Q40478934-49C86754-EBFB-4BF4-BF73-8745E399BC58Q40551481-3143F8B9-E588-4694-911A-8005BC5D4734Q42555717-4B30CFDC-C8F6-4CE5-BB7A-8927CE95B967Q43158692-CA437C77-B3D4-4754-BAA4-83A8AB8C4F7CQ43159235-7F8F09B1-2CEE-4C9D-A087-2E0B9F03CC3FQ44932093-8176036A-70C0-415F-B247-897A93248A6CQ45048364-214E8F16-C77D-4FF0-9782-6C088BDB0803Q45099620-383E1AC5-9052-43D5-A971-7909822B31FCQ45552205-3ECA4C35-23F2-477B-BCDE-F98292BFB13FQ46414199-82C07508-F875-45C3-B459-F84FBA130274Q46850181-C05DEAB6-D332-4C0F-85BC-70B94284D251Q50072029-D734E08A-AFC3-41B4-B7D9-B6E36118BE92Q50455563-01780F43-958A-4229-A2F9-A2E5C6D4DF5EQ50509073-5B913B44-3A76-4793-AFBF-03A0D65F85E1Q50561961-02D2BAAA-AB0B-41DB-B472-97870E2E96E8Q55512054-2B1CD5AD-FE20-4FA7-99BC-3A2FB9AA6D2E
P2860
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@ast
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@en
type
label
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@ast
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@en
prefLabel
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@ast
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@en
P2093
P1476
Therapeutic drug monitoring of ...... metabolites in Crohn disease.
@en
P2093
P356
10.1080/00365520150218084
P577
2001-01-01T00:00:00Z